Salivary anti-cyclic citrullinated peptide as a screening tool for rheumatoid arthritis
This study aims to evaluate the sensitivity and specificity of salivary anti-cyclic citrullinated peptide 3 (anti-CCP3) for the early diagnosis of rheumatoid arthritis. Between June 2017 and April 2019, a total of 63 patients with rheumatoid arthritis (10 males, 53 females; mean age: 50.4±9.5 years;...
Saved in:
Published in | Archives of rheumatology Vol. 38; no. 1; pp. 95 - 100 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Turkey
Turkish League Against Rheumatism
01.03.2023
Prof Sebnem Ataman, President Turkish League Against Rheumatism |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | This study aims to evaluate the sensitivity and specificity of salivary anti-cyclic citrullinated peptide 3 (anti-CCP3) for the early diagnosis of rheumatoid arthritis.
Between June 2017 and April 2019, a total of 63 patients with rheumatoid arthritis (10 males, 53 females; mean age: 50.4±9.5 years; range, 27 to 74 years) and 49 healthy controls (8 males, 41 females; mean age: 49.3±9.3 years; range 27 to 67 years) were included. Salivary samples were collected by passive drooling. Anti-cyclic citrullinated peptide analyses of salivary and serum samples were performed.
The mean polyclonal immunoglobulin (Ig)G-IgA anti-CCP3 salivary levels were significantly different in patients (149.2±134.2) compared to healthy controls (28.5±23.9). The mean polyclonal IgG-IgA anti-CCP3 serum levels were measured as 254.0±169.5 in patients and 3.8±3.6 in healthy individuals. The diagnostic accuracy analysis of salivary IgG-IgA anti-CCP3 results in an area under the curve (AUC) of 0.818, as well as 91.84% specificity and 61.90% sensitivity.
Salivary anti-CCP3 may be considered as an additional screening test for rheumatoid arthritis. |
---|---|
ISSN: | 2148-5046 1309-0291 2618-6500 1309-0283 |
DOI: | 10.46497/ArchRheumatol.2023.9032 |